Investing
Sales of short-term available-for-sale investments
Moderna Sales of short-term available-for-sale investments decreased by 1.1% to $602.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.5%, from $688.00M to $602.00M. Over 4 years (FY 2021 to FY 2025), Sales of short-term available-for-sale investments shows a downward trend with a -6.7% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
First reportedQ1 2016
Last reportedQ1 2026May 1, 2026
Metric ID:
adi_sales_of_short_term_investmentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.46B | $277.00M | $1.12B | $1.38B | $1.13B | $412.00M | $630.00M | $1.96B | $470.00M | $298.00M | $481.00M | $1.29B | $714.00M | $1.01B | $957.00M | $688.00M | $371.00M | $685.00M | $609.00M | $602.00M |
| QoQ Change | — | -81.1% | +305.1% | +22.7% | -18.0% | -63.5% | +52.9% | +210.6% | -76.0% | -36.6% | +61.4% | +167.2% | -44.4% | +41.6% | -5.3% | -28.1% | -46.1% | +84.6% | -11.1% | -1.1% |
| YoY Change | — | — | — | — | -22.9% | +48.7% | -43.9% | +42.1% | -58.4% | -27.7% | -23.7% | -34.3% | +51.9% | +239.3% | +99.0% | -46.5% | -48.0% | -32.2% | -36.4% | -12.5% |
Range$277.00M – $1.96B
CAGR-17.1%
Avg YoY Growth+5.9%
Median YoY Growth-25.7%
Current Streak2 quarters decline
Sales of short-term available-for-sale investments at Other Companies
Frequently Asked Questions
- What is Moderna's sales of short-term available-for-sale investments?
- Moderna (MRNA) reported sales of short-term available-for-sale investments of $602.00M in Q1 2026.
- How has Moderna's sales of short-term available-for-sale investments changed year-over-year?
- Moderna's sales of short-term available-for-sale investments decreased by 12.5% year-over-year, from $688.00M to $602.00M.
- What is the long-term trend for Moderna's sales of short-term available-for-sale investments?
- Over 4 years (2021 to 2025), Moderna's sales of short-term available-for-sale investments has grown at a -6.7% compound annual growth rate (CAGR), from $3.11B to $2.35B.